Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Takashi Futamura"'
Autor:
Naoki Amada, Tsuyoshi Hirose, Mikio Suzuki, Yusuke Kakumoto, Takashi Futamura, Kenji Maeda, Tetsuro Kikuchi
Publikováno v:
Neuropsychopharmacology Reports, Vol 43, Iss 1, Pp 132-136 (2023)
Abstract Aim Selective serotonin reuptake inhibitors (SSRIs) are used to treat major depressive disorder (MDD) and other psychiatric disorders (e.g., obsessive compulsive disorder, social anxiety disorder, and panic disorder). In MDD treatment, SSRIs
Externí odkaz:
https://doaj.org/article/539a2a2ea0d34f5d8379ae7d122281e2
Publikováno v:
Neuropsychopharmacology Reports, Vol 42, Iss 3, Pp 263-271 (2022)
Abstract Background Deficiency of folate, an essential vitamin for DNA synthesis and methylation, is reported as a risk factor for mental disorders. Considering a possibility that folate metabolism deficit during pregnancy may disturb CNS development
Externí odkaz:
https://doaj.org/article/37482cd7e51441629de23efff9144573
Autor:
Satoshi Akiyama, Hirotaka Nagai, Shota Oike, Io Horikawa, Masakazu Shinohara, Yabin Lu, Takashi Futamura, Ryota Shinohara, Shiho Kitaoka, Tomoyuki Furuyashiki
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Severe and prolonged social stress induces mood and cognitive dysfunctions and precipitates major depression. Neuroinflammation has been associated with chronic stress and depression. Rodent studies showed crucial roles of a few inflammation
Externí odkaz:
https://doaj.org/article/567ebe43dd94438ba727a55d27ace8dc
Autor:
Tetsuro Kikuchi, Kenji Maeda, Mikio Suzuki, Tsuyoshi Hirose, Takashi Futamura, Robert D. McQuade
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 2, Pp 134-143 (2021)
Abstract Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2
Externí odkaz:
https://doaj.org/article/52c7780e7f80417e97c13f70502cc28d
Autor:
Naoki Amada, Hitomi Akazawa, Yuta Ohgi, Kenji Maeda, Haruhiko Sugino, Nobuyuki Kurahashi, Tetsuro Kikuchi, Takashi Futamura
Publikováno v:
Neuropsychopharmacology Reports, Vol 39, Iss 4, Pp 279-288 (2019)
Abstract Background Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D2 receptor sensitization. We evaluated the effects of brexp
Externí odkaz:
https://doaj.org/article/66b91c71c5e2434aa05a0dc090222e04
Autor:
Emiliano Tamanini, Shin Miyamura, Ildiko M. Buck, Benjamin D. Cons, Lee Dawson, Charlotte East, Takashi Futamura, Shintaro Goto, Charlotte Griffiths-Jones, Tetsuya Hashimoto, Tom D. Heightman, Shunpei Ishikawa, Hideki Ito, Yosuke Kaneko, Tatsuya Kawato, Kazumi Kondo, Naoki Kurihara, James M. McCarthy, Yukiko Mori, Tsuyoshi Nagase, Yuichiro Nakaishi, Judith Reeks, Akimasa Sato, Patrick Schöpf, Kuninori Tai, Taichi Tamai, Dominic Tisi, Alison J.-A. Woolford
Publikováno v:
ACS Medicinal Chemistry Letters. 13:1591-1597
Fragment-based ligand discovery was successfully applied to histone deacetylase HDAC2. In addition to the anticipated hydroxamic acid- and benzamide-based fragment screening hits, a low affinity (∼1 mM) α-amino-amide zinc binding fragment was iden
Autor:
Tsuyoshi Hirose, Mikio Suzuki, Kenji Maeda, Takashi Futamura, Robert D. McQuade, Tetsuro Kikuchi
Publikováno v:
Neuropsychopharmacology Reports
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2002 and h
Autor:
Nobuyuki Kurahashi, Naoki Amada, Hitomi Akazawa, Tetsuro Kikuchi, Haruhiko Sugino, Takashi Futamura, Yuta Ohgi, Kenji Maeda
Publikováno v:
Neuropsychopharmacology Reports. 39:279-288
Background Long-term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D2 receptor sensitization. We evaluated the effects of brexpiprazole on
Autor:
Tomohiro Usami, Tetsuro Kikuchi, Takashi Futamura, Kazunari Niidome, Kenji Maeda, Mikio Suzuki
Publikováno v:
Folia Pharmacologica Japonica. 154:275-287
Brexpiprazole (Rexulti®) is the second antipsychotic agent in the world with dopamine D2 receptor partial agonist which was developed by Otsuka Pharmaceutical Co. Ltd. It is categorized as 〝Serotonin- dopamine Activity Modulator (SDAM)〟 that reg
Autor:
Robert D. McQuade, Tsuyoshi Hirose, Maeda Kenji, Tetsuro Kikuchi, Takashi Futamura, Mikio Suzuki, Sakiko Yamada
Publikováno v:
NeuroPsychopharmacotherapy ISBN: 9783319560151
NeuroPsychopharmacotherapy
NeuroPsychopharmacotherapy ISBN: 9783030620585
NeuroPsychopharmacotherapy
NeuroPsychopharmacotherapy ISBN: 9783030620585
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1d0ba6824ed2747e2acdf297ab1bbf
https://doi.org/10.1007/978-3-319-56015-1_424-1
https://doi.org/10.1007/978-3-319-56015-1_424-1